Evidence map›Paper›PMID 42367045›Full record

ArticleJournal of medicinal chemistry2026

Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2.

Hua Tang, Yaxian Liao, Tsung-Yu Yeh, Kazuya Nishibayashi, Milad Rouhimoghadam, Ka Yang, Chunrong Li, Regina Stasser de Gonzalez, Yuan Zhao, Nina J Hawkins and 3 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hua TangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Yaxian LiaoDepartment of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Tsung-Yu YehLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0001-7812-5290
Kazuya NishibayashiLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Milad RouhimoghadamTechnology & Therapeutic Platforms, AbbVie Incorporated, North Chicago, Illinois 60064, United States.
Ka YangDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0001-8937-7397
Chunrong LiLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Regina Stasser de GonzalezLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Yuan ZhaoLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Nina J HawkinsLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Justin M ReitsmaTechnology & Therapeutic Platforms, AbbVie Incorporated, North Chicago, Illinois 60064, United States.ORCID 0000-0002-2700-6440
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, United States.ORCID 0000-0001-7626-0034
Weiping TangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0002-0039-3196

Funding

NMR User Program at NMRFAMR24GM141526 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine Anne Henzler-Wildman · 2021 to 2026
$6.4M
Chemical Synthesis and Biological Application of Carbohydrates and Glycoconjugates - Admin SupplementR35GM148266 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Weiping Tang · 2023 to 2026
$1.8M
NIGMS NIH HHS R24 GM141526NIGMS NIH HHS R35 GM148266
6 · The paper itself

Abstract

Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, yet the repertoire of E3 ligase recruiters remains limited. Here, we report the discovery of an aldehyde-anchored PROTAC that covalently engages the E3 ligase FBXO22 to induce degradation of the histone methyltransferase NSD2 and CDK12. Competitive electrophile screening identified a phenyl aldehyde warhead as optimal, with SAR studies revealing that degradation is highly sensitive to the steric and electronic environment of the aldehyde moiety. The lead degrader, T9, effectively and selectively induces NSD2 degradation across multiple cancer cell lines. Mechanistic investigations confirmed that degradation is dependent on FBXO22, the ubiquitin-proteasome system, and the neddylation pathway, with mutagenesis identifying Cys326 as the critical residue for covalent engagement. This work establishes a stable covalent ligand for FBXO22, expanding chemical space of PROTAC design by introducing an accessible aldehyde-based E3 ligase ligand with broad potential for protein degradation.

Indexed as

AldehydesF-Box ProteinsHistone-Lysine N-MethyltransferaseProteolysisRepressor ProteinsSmall Molecule LibrariesCell Line, TumorHumansProteolysis Targeting ChimeraReceptors, Cytoplasmic and NuclearStructure-Activity RelationshipAldehydesF-Box ProteinsFBXO22 protein, humanHistone-Lysine N-MethyltransferaseNSD2 protein, humanProteolysis Targeting ChimeraReceptors, Cytoplasmic and NuclearRepressor ProteinsSmall Molecule LibrariesaldehydecovalentdegradationE3FBXO22ligandligaseNSD2PROTACprotein

Identifiers

PMID42367045
PMCPMC13370883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.